Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well everolimus works in treating patients with
relapsed or refractory multiple myeloma.